Abstract
Realistic and renewable laboratory models that accurately reflect the distinct clinical features of childhood cancers have enormous potential to speed research progress. These models help us to understand disease biology, develop new research methods, advance new therapies to clinical trial, and implement personalized medicine. This chapter describes methods to generate patient-derived xenograft models of neuroblastoma and rhabdomyosarcoma, two tumor types for which children with high-risk disease have abysmal survival outcomes and survivors have lifelong-debilitating effects from treatment. Further, this protocol addresses model development from diverse clinical tumor tissue samples, subcutaneous and orthotopic engraftment, and approaches to avoid model loss.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ward ZJ, Yeh JM, Bhakta N et al (2019) Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol 20(7):972–983. https://doi.org/10.1016/s1470-2045(19)30273-6
Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013. https://doi.org/10.1158/2159-8290.Cd-14-0001
Zhang X, Claerhout S, Prat A et al (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73(15):4885–4897. https://doi.org/10.1158/0008-5472.Can-12-4081
Izumchenko E, Paz K, Ciznadija D et al (2017) Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 28(10):2595–2605. https://doi.org/10.1093/annonc/mdx416
Lau LMS, Mayoh C, Xie J et al (2022) In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. EMBO Mol Med 14(4):e14608. https://doi.org/10.15252/emmm.202114608
Steliarova-Foucher E, Colombet M, Ries LAG et al (2017) International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol 18(6):719–731. https://doi.org/10.1016/s1470-2045(17)30186-9
Park JR, Eggert A, Caron H (2010) Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24(1):65–86. https://doi.org/10.1016/j.hoc.2009.11.011
Dasgupta R, Fuchs J, Rodeberg D (2016) Rhabdomyosarcoma. Semin Pediatr Surg 25(5):276–283. https://doi.org/10.1053/j.sempedsurg.2016.09.011
Pinto NR, Applebaum MA, Volchenboum SL et al (2015) Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 33(27):3008–3017. https://doi.org/10.1200/jco.2014.59.4648
Punyko JA, Mertens AC, Baker KS et al (2005) Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 103(7):1475–1483. https://doi.org/10.1002/cncr.20929
London WB, Bagatell R, Weigel BJ et al (2017) Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer 123(24):4914–4923. https://doi.org/10.1002/cncr.30934
Raney RB, Anderson JR, Barr FG et al (2001) Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23(4):215–220. https://doi.org/10.1097/00043426-200105000-00008
Cohen LE, Gordon JH, Popovsky EY et al (2014) Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant 49(4):502–508. https://doi.org/10.1038/bmt.2013.218
Applebaum MA, Henderson TO, Lee SM et al (2015) Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 62(1):128–133. https://doi.org/10.1002/pbc.25249
Clement S, Schoot R, Slater O et al (2016) Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. Eur J Cancer 54:1–10
Schoot RA, Slater O, Ronckers CM et al (2015) Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer 51(11):1424–1434
Youn P, Milano MT, Constine LS et al (2014) Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer 120(15):2334–2342
Kamili A, Gifford AJ, Li N et al (2020) Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. Br J Cancer 122(5):680–691. https://doi.org/10.1038/s41416-019-0682-4
Stewart E, Federico SM, Chen X et al (2017) Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549(7670):96–100. https://doi.org/10.1038/nature23647
Meehan TF, Conte N, Goldstein T et al (2017) PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Res 77(21):e62–e66. https://doi.org/10.1158/0008-5472.CAN-17-0582
Bondarenko G, Ugolkov A, Rohan S et al (2015) Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia 17(9):735–741. https://doi.org/10.1016/j.neo.2015.09.004
Mukohyama J, Iwakiri D, Zen Y et al (2016) Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens. Oncotarget 7(31):50150–50160. https://doi.org/10.18632/oncotarget.10322
Butler KA, Hou X, Becker MA et al (2017) Prevention of human lymphoproliferative tumor formation in ovarian cancer patient-derived xenografts. Neoplasia 19(8):628–636. https://doi.org/10.1016/j.neo.2017.04.007
Ito R, Katano I, Kawai K et al (2009) Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 87(11):1654–1658. https://doi.org/10.1097/TP.0b013e3181a5cb07
Acknowledgments
The authors thank the patients, clinicians, and researchers of the Sydney Children’s Hospital Network, the Sydney Children’s Tumour Bank Network, and the Zero Childhood Cancer initiative for providing samples with which we were able to establish this methodology. Children’s Cancer Institute Australia is affiliated with the University of New South Wales Sydney and the Sydney Children’s Hospital Network.
This protocol was developed from studies supported by the Kids Cancer Alliance, a Cancer Institute New South Wales Translational Cancer Research Centre and by Neuroblastoma Australia.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Hanssen, K.M., Fletcher, J.I., Kamili, A. (2024). Generation of Orthotopic and Subcutaneous Patient-Derived Xenograft Models from Diverse Clinical Tissue Samples of Pediatric Extracranial Solid Tumors. In: Saad, M.I. (eds) Patient-Derived Xenografts. Methods in Molecular Biology, vol 2806. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3858-3_6
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3858-3_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3857-6
Online ISBN: 978-1-0716-3858-3
eBook Packages: Springer Protocols